Trumps new crown treatment two pronged approach: cocktail therapy and radcivir

category:Hot
 Trumps new crown treatment two pronged approach: cocktail therapy and radcivir


The companys chief executive, Leonard Shriver, told CNN that Trumps immune system is in a race against the virus, and if the virus wins, it could have terrible consequences, and what his companys antibodies can provide is to make the race fair.

Besides, SeanP.Conley In a memo, it was also confirmed that trump had received 8 grams of mixed antibodies against regenerant, in addition to taking zinc, vitamin D, famotidine, melatonin and aspirin every day. According to CNBC, in a statement issued by regenerant, the company provided trump with the dose in response to Dr. Trumps compassionate use request.

It is worth mentioning that in addition to receiving antibody therapy, on October 3, Kayleigh mcenany, the US White House press secretary, shared a message from Dr. trump on October 3, saying that trump does not need oxygen supplement at present, but is currently receiving treatment with redcivir. Tweet screenshot of Kayleigh mcenany, White House Press Secretary

Radcivir has attracted much attention during the outbreak of the new crown disease and is a potential therapeutic drug developed by Gilead science. In contrast, regenerants cocktail antibody therapy is relatively unfamiliar.

Nasq: regn is a biotechnology company in the United States, which has a history of over 30s. At present, it has 7 kinds of treatment methods approved by FDA and the research and development of many candidate products. The product pipeline covers the fields of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

In response to the new outbreak, Zaiyuan has developed an antibody therapy called regn-cov2. According to its official website, this is a combination of two monoclonal antibodies (regn10933 and regn10987) designed to block the infectivity of the new coronavirus.

Preclinical studies have shown that regn-cov2 reduces the number of viruses and associated damage in the lungs of non-human primates. On September 19, regen released data showing that regn-cov2 can reduce virus levels and improve symptoms in hospitalized covid-19 patients.

Antibody therapy is one of the potential tools to deal with the new coronal epidemic

The antibody therapy for new coronavirus is not the only company. AstraZeneca, GlaxoSmithKline and Eli Lilly have also developed antibody therapy to fight against the new coronavirus.

There is also progress in the development of new antibodies against AstraZeneca. At the end of August, AstraZeneca was exposed and had begun testing an antibody cocktail therapy. AstraZenecas antibody therapy, named azd7442, is a combination of two monoclonal antibodies (mAbs), also known as cocktail therapy.

Ly-cov555, a major antibody developed by Eli Lilly and abcellera, a biotechnology company, entered phase III trials in early August. Novel coronavirus pneumonia was first introduced in June 2nd, and it was the first potential antibody therapy for new crown pneumonia, which promoted human trials.

GlaxoSmithKline (GSK) cooperated with virbiotechnology to develop a new coronavirus neutralizing antibody vir-7831 (also known as gsk4182136). In early September, GSK completed the first patient administration in the phase 2 / 3 clinical trial.

In China, the antibody therapy of Junshi biology has attracted much attention. On July 13, Jun Shi bio (01877. HK) announced that the phase 1 clinical trial of recombinant all human monoclonal antibody injection (product code js016) developed jointly with the Institute of Microbiology, Chinese Academy of Sciences, has been completed.

(function(){( window.slotbydup=window .slotbydup||[]).push({id:u5811557,container:ssp_ 5811557, async:true }Li Ning, CEO of Junshi biology, revealed in an exclusive interview with surging journalists that Junshi bio hopes to complete clinical research in the third quarter as soon as possible, at least in the early stage of clinical research in patients with new crown. It is worth mentioning that Lilly and Junshi biology have also reached a cooperation agreement on js016. According to the agreement, Eli Lilly will obtain exclusive license for clinical development, production and commercialization of products outside the Greater China region. For this purpose, Lilly will pay a down payment of US $10 million to Junshi bio, and a maximum milestone payment of US $245 million to Junshi bio after each js016 (single or combined) reaches the specified milestone, plus the net sales of the product A two digit percentage of the sales share. Extended reading of Trump: the treatment went well, and the doctor said he was in good condition and had been used by radsey New York Times: trump has received a state-of-the-art experimental therapy media: trump received cocktail therapy and also took vitamin D and melatonin. Source: surging news editor in charge: Huang Jiadi_ NNB6466

Li Ning, CEO of Junshi biology, revealed in an exclusive interview with surging journalists that Junshi bio hopes to complete the clinical research as soon as possible in the third quarter, at least in the early clinical research of patients with new crown.

It is worth mentioning that Lilly and Junshi biology have also reached a cooperation agreement on js016.

According to the agreement, Eli Lilly will obtain exclusive license for clinical development, production and commercialization of products outside the Greater China region. For this purpose, Lilly will pay a down payment of US $10 million to Junshi bio, and a maximum milestone payment of US $245 million to Junshi bio after each js016 (single or combined) reaches the specified milestone, plus the net sales of the product A two digit percentage of the sales share.